Upadacitinib Treatment Indications
Upadacitinib is a treatment for multiple immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease 1.
Approved Indications by Disease Category
Rheumatic Diseases
- Rheumatoid Arthritis (RA): Approved at 15 mg daily for moderate-to-severe disease 2, 1
- Psoriatic Arthritis (PsA): Phase 3 trials demonstrated efficacy at 15 mg and 30 mg doses, showing non-inferiority to adalimumab at 15 mg and superiority at 30 mg 2
- Ankylosing Spondylitis (AS): Demonstrated significant efficacy at 15 mg daily in phase 2/3 trials, with 52% achieving ASAS 40 response versus 26% with placebo at week 14 2
- Non-radiographic Axial Spondyloarthritis (nr-axSpA): Approved based on clinical trial evidence 3, 4
Dermatologic Diseases
- Atopic Dermatitis (AD): Approved for moderate-to-severe disease, with marked clinical improvement in disease severity, pruritus, and quality of life 3, 5
Gastrointestinal Diseases
Ulcerative Colitis (UC): FDA-approved for moderate-to-severe active disease in patients with inadequate response, loss of response, or intolerance to conventional or biologic therapy 2, 6
- Induction: 45 mg daily for 8 weeks (up to 16 weeks if needed)
- Maintenance: 15 mg or 30 mg daily
Crohn's Disease (CD): Approved based on promising phase 2 and phase 3 trial results 2, 3
Mechanism of Action Context
Upadacitinib functions as a selective JAK1 inhibitor that modulates cytokine signaling pathways central to inflammatory disease pathogenesis 7, 1. It demonstrates greater inhibitory potency at JAK1 and JAK2 relative to JAK3 and TYK2, though the clinical relevance of specific JAK enzyme inhibition remains under investigation 1.
Disease-Specific Dosing Considerations
The 2025 expert consensus emphasizes using disease-specific recommended doses 7. Dose adjustments should be considered for:
- Patients with higher age
- Significant renal impairment (CrCl <60 mL/min requires consideration)
- Hepatic impairment
- Drug interactions (particularly with CYP3A4 inhibitors/inducers like ketoconazole or rifampicin) 7, 2
Emerging Off-Label Use
Recent evidence suggests increasing off-label use in acute severe ulcerative colitis (ASUC) and severe Crohn's disease flares, though this represents a new treatment strategy requiring further validation 8, 9.
Safety Profile Across Indications
Long-term safety data from over 27,000 patient-years demonstrates consistent safety profiles across indications 4. Key adverse events of special interest include herpes zoster (2.4-6.6 per 100 patient-years), serious infections (1.3-4.6 per 100 patient-years), and venous thromboembolism (0-0.9 per 100 patient-years), with rates remaining stable over time 4.